Laboratory experiments in human bronchial epithelial cells show that dual-corrector drug combinations can rescue both processing and chloride channel function in an ultra-rare cystic fibrosis CFTR variant, F1078S. The study’s core contribution is functional: it reports restoration of CFTR activity rather than only improved protein expression. That distinction matters for ultra-rare genotypes, where patient-level clinical evidence is often limited. If the combination strategy progresses, it could inform individualized treatment development for patients whose genotypes currently lack robust evidence for existing CFTR modulators.
Get the Daily Brief